Clearmind Expands Alcohol Use Trial
Ticker: CMND · Form: 6-K · Filed: Jul 15, 2025 · CIK: 1892500
| Field | Detail |
|---|---|
| Company | Clearmind Medicine INC. (CMND) |
| Form Type | 6-K |
| Filed Date | Jul 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, expansion, healthcare
TL;DR
Clearmind expands alcohol trial, adds new site & patient.
AI Summary
Clearmind Medicine Inc. announced on July 15, 2025, that it has expanded its clinical trial for alcohol use disorder by activating a new site and enrolling an additional participant. This expansion is part of their ongoing efforts to develop treatments for alcohol use.
Why It Matters
This expansion could accelerate the development of Clearmind's potential treatment for alcohol use disorder, potentially impacting a significant public health issue.
Risk Assessment
Risk Level: medium — Clinical trial expansions are common but carry inherent risks related to trial success, regulatory approval, and market adoption.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- July 15, 2025 (date) — Press release date
- 001-41557 (other) — Commission file number
- 333-275991 (other) — Registration statement file number
- 333 (other) — Registration statement file number
FAQ
What is the specific title of the press release incorporated into this 6-K filing?
The press release is titled 'Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled'.
On what date was the press release issued?
The press release was issued on July 15, 2025.
What is the primary focus of the clinical trial mentioned in the filing?
The clinical trial is focused on alcohol use.
What are the two key developments announced in the press release regarding the clinical trial?
A new site has been activated, and an additional participant has been enrolled.
Which SEC registration statements are referenced in relation to this filing?
Registration Statements on Form F-3, File Nos. 333-275991 and 333, are referenced.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 15, 2025 regarding Clearmind Medicine Inc. (CMND).